Peel Hunt25 Jan 2021 16:04
Peel hunt say sensyne is a buy.
Sensyne’s clinical AI expertise, and its access to one of the richest and best-structured healthcare datasets in the world, underpins a business model which enables healthcare providers to monetise their patient data sustainably and ethically while improving discovery research and reducing drug development timelines.
Recent strategic collaborations, and the first US launch of one of its leading software products in December, support our expectations of a hockey-stick in revenues over the next 12-18 months, and base case/bull case upsides of 2.2x and 6x respectively.
From proactive investors. Sounds good to me